Mnuchin told CNBC that he's confident President Donald Trump and President Xi Jinping can make progress in stalled trade talks.World Economyread more
U.S. stock index futures jumped Wednesday morning after Treasury Secretary Steven Mnuchin told CNBC that the U.S. and China were almost there on a trade deal.US Marketsread more
President Donald Trump's administration hopes additional sanctions on Iran will force the country to negotiate.Politicsread more
Democrats want Mueller's testimony on his probe into Russian interference in the 2016 election and Trump's efforts to influence it.Politicsread more
Stocks should rally if the U.S. and China agree to new negotiations and a ceasefire in the trade war, but the economic impact of tariffs will continue.Market Insiderread more
Bitcoin surged as high as $12,919 in early morning trade Wednesday, to its highest level since January 2018.Technologyread more
The trade war between Beijing and Washington appears to have depressed Chinese property purchases in the United States. China's own actions may also be playing a role.Real Estateread more
Tesla CEO Elon Musk sent out another email to his employees, pushing them to aim for a record number of vehicle deliveries to end the second quarter of 2019.Technologyread more
More than 300 companies are talking to government officials in Washington about how detrimental the trade war is.Marketsread more
The Senate is expected to pass its own version of the border aid legislation, while the Trump administration has threatened to veto both bills.Politicsread more
Some 4 million people have fled the South American country since 2015 amid an economic meltdown.World Politicsread more
* Says to halt two late-stage clinical trials of crenezumab
* Says committed to ongoing clinical studies in Alzheimer's
* Roche was working on crenezumab with AC Immune (Adds background about failed trials, share expectations)
ZURICH, Jan 30 (Reuters) - Roche Holding will halt two late-stage clinical trials of its crenezumab drug for early Alzheimer's disease after an interim analysis indicated it was unlikely to hit its primary goal, the Swiss drugmaker said on Wednesday.
The announcement by Roche, which has been working on the product with Swiss-based partner AC Immune, marks the latest high-profile failure of Alzheimer's disease drugs following the 2016 flop of an experimental medicine from Eli Lilly, among others.
These failures have undermined conviction in the so-called beta amyloid treatment hypothesis, in which a protein forms plaques in the brain and is believed to play a pivotal role in the disorder.
Roche said an Alzheimer's Prevention Initiative (API) study of crenezumab in familial Alzheimer's disease in Colombia would continue and that it remained committed to ongoing clinical studies in Alzheimer's disease, including separate phase-III trials with gantenerumab and a phase-II anti-tau trial that seek to tackle the debilitating brain-wasting sickness.
AC Immune Chief Executive Andrea Pfeifer said the company was "extremely disappointed" by the news, adding that she was still hopeful the study in Colombia -- focusing on cognitively healthy individuals with a genetic mutation who are at risk of developing Alzheimer's disease -- would turn out more positively.
Roche shares were indicated 0.8 percent lower, premarket indicators showed.
AC Immune shares are expected to fall sharply when they begin trading.
Alzheimer's is a compelling target for drugmakers as the affected population increases, but treating the disease has proven elusive.
Last year, Eli Lilly and AstraZeneca Plc discontinued late-stage trials testing their Alzheimer's treatment, joining a slew of drugmakers to stop developing treatments for the memory-robbing disease.
Experimental Alzheimer's drugs have had a dismal track record, with more than 100 failures.
Johnson and Johnson also stopped mid-stage trials testing prospective medicines. (Additional reporting by Michael Shields; editing by Maria Sheahan and Jason Neely)